Anti-VEGF-A (Brolucizumab), Humanized Antibody

Anti-VEGF-A (Brolucizumab), Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a humanized single-chain Fv (scFv) antibody fragment that targets vascular endothelial growth factor A (VEGF-A). VEGF-A is a pro-angiogenic protein that plays a significant role in the pathogenesis of several diseases such as age-related macular degeneration, cancer, and diabetic retinopathy. Binding of VEGF-A to its receptor activates several downstream proteins such as PI3K, Ras, and MAPK, and promotes proliferation, growth, and migration of endothelial cells. The antibody binds to VEGF-A and prevents binding to its receptors, thereby inhibiting neovascularization, vascular permeability, and proliferation of endothelial cells. The small size of the antibody not only allows it to retain the ability to bind to its target protein, but also provides efficient penetration into the retina and choroid, and faster clearance from the system. The original antibody received approval from the FDA to treat wet age-related macular degeneration

Immunogen Sequence:Human VEGFA

Target Alternative Name:ESBA-1008, ESBA1008, RTH-258, RTH258, VPF, VEGF, MVCD1, VEGFA

Species Reactivities:Human

Tag Line:The biosimilar is a humanized scFv antibody fragment that targets VEGF-A and prevents neovascularization and proliferation of endothelial cells. The original monoclonal antibody is approved to treat wet age-related macular degeneration

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.